Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

Heart failure (HF) is growing to a modern epidemic and despite advances in therapy, it still
carries an ominous prognosis and a significant socioeconomic burden. 1 Many novel agents …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

Primary percutaneous coronary intervention is nowadays the preferred reperfusion strategy
for patients with acute ST-segment–elevation myocardial infarction, aiming at restoring …

To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers
in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

Lethal reperfusion injury is a paradoxical type of myocardial injury caused by the restoration
of coronary blood flow after an ischemic episode. This review focuses on the mechanisms of …